查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1307843

先天代謝異常用醫療食品全球市場 - 產業趨勢和2030年為止的預測

Global Medical Foods for Inborn Errors of Metabolism Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 642 Pages | 商品交期: 請詢問到貨日

價格

全球先天代謝異常用醫療食品市場規模在2022年估算為24億7,781萬美金。該市場在2023年～2030年的預測期間將以13.5％的年複合成長率擴大，到2030年達到67億1,716萬美元。

本報告提供全球先天代謝異常用醫療食品市場相關調查，提供市場概要，以及各產品，各疾病，各年齡層，不同形態，包裝，各流通管道，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 高級見解

第5章 開發平台分析

第6章 流行病學

第7章 產業考察

第8章 醫療食品法規情勢

第9章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第10章 全球先天代謝異常用醫療食品市場，各產品

  • 概要
  • 氨基酸
  • 低蛋白質食品
  • 含有 GMP 氨基酸修飾的含鐵嬰兒配方奶粉的 Glytactin
  • 低鈣/無維生素 D 含鐵嬰兒配方奶粉
  • 其他

第11章 全球先天代謝異常用醫療食品市場，各疾病

  • 概要
  • 苯酮尿症(PKU)
  • 酪胺酸血症I型及II型
  • 楓糖尿症(MSUD)
  • 高胱胺酸尿症
  • I 型戊二酸血症
  • 尿素循環障礙
  • 甲基丙二酸血症
  • 異戊酸血症
  • 有機酸味劑
  • 腎臟病
  • 丙酸血症
  • 白氨酸代謝障礙
  • 其他

第12章 全球先天代謝異常用醫療食品市場，各年齡層

  • 概要
  • 幼兒
  • 嬰兒
  • 青年成人
  • 成人

第13章 全球先天代謝異常用醫療食品市場，不同形態

  • 概要
  • 粉末
  • 液體
  • 錠劑
  • 凝膠
  • 其他

第14章 全球先天代謝異常用醫療食品市場，包裝

  • 概要
  • 罐
  • 包
  • 瓶
  • 瓶
  • 其他

第15章 全球先天代謝異常用醫療食品市場，各流通管道

  • 概要
  • 醫院藥局
  • 零售藥局
  • 藥妝店
  • 線上藥局
  • 其他

第16章 全球先天代謝異常用醫療食品市場，各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第17章 全球先天代謝異常用醫療食品市場，企業形勢

第18章 SWOT分析

第19章 企業簡介

  • ABBOTT
  • NESTLE HEALTH SCIENCE
  • AJINOMOTO CAMBROOKE, INC.
  • MEAD JOHNSON & COMPANY, LLC.
  • NUTRICIA
  • APR
  • B.BRAUN SE

The global medical foods for inborn errors of metabolism market is expected to reach USD 6,717.16 million by 2030 from USD 2,477.81 million in 2022, growing at a CAGR of 13.5% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Global Medical Foods for Inborn Errors of Metabolism Market, By Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Low Protein Food, and Others), Age Group (Infants, Weaning, Adolescent, and Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I and II, Urea Cycle Disorders, and Others), Forms (Powder, Liquid, Tablets, Gels, and Others), Packaging (Can, Jar, Packets, Bottle, and Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Drug Stores, Online Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Finland, Denmark, Sweden, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, New Zealand, Vietnam, Philippines, Taiwan, Rest of Asia-Pacific Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Qatar, Egypt, Oman, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Medical Foods for Inborn Errors of Metabolism Market Dynamics

  • Driver
  • Increase in the incidence of IEMs
  • Restraint
  • High cost associated with medical food products
  • Opportunity
  • Preference of dietary supplements over enzyme replacement therapy

Market Players

Some of the major market players operating in the global medical foods for inborn errors of metabolism are:

  • Abbott
  • Nestle Health Science (A Subsidiary of Nestle)
  • Ajinomoto Cambrooke, Inc. (A Subsidiary of Ajinomoto Co., Inc.)
  • Mead Johnson & Company, LLC. (A Subsidiary of Reckitt Benckiser Group plc.)
  • Nutricia (A Subsidiary of Danone)
  • Baxter
  • Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
  • Meiji Holdings Co., Ltd.
  • B. Braun SE
  • Dr. Schar AG / SPA
  • Kate Farms
  • Hexagonnutrition Ltd.
  • Primus Pharmaceuticals, Inc.
  • Ener-G Foods, Inc.
  • PKU Perspectives
  • Piam Farmaceutici S.P.A.
  • Promin Metabolics
  • Orpharma Pty Ltd.
  • Pristine Organics Private Limited
  • Solace Nutrition
  • EBM Medical
  • Galen Limited
  • PKU-Mdmil
  • APR

TABLE OF CONTENTS

1 INTRODUCTION 60

  • 1.1 OBJECTIVES OF THE STUDY 60
  • 1.2 MARKET DEFINITION 60
  • 1.3 OVERVIEW 60
  • 1.4 CURRENCY AND PRICING 62
  • 1.5 LIMITATIONS 62
  • 1.6 MARKETS COVERED 62

2 MARKET SEGMENTATION 68

  • 2.1 MARKETS COVERED 68
  • 2.2 GEOGRAPHICAL SCOPE 69
  • 2.3 YEARS CONSIDERED FOR THE STUDY 70
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 71
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
  • 2.6 MULTIVARIATE MODELLING 75
  • 2.7 PRODUCTS LIFELINE CURVE 75
  • 2.8 DBMR MARKET POSITION GRID 76
  • 2.9 SECONDARY SOURCES 78
  • 2.10 ASSUMPTIONS 78

3 EXECUTIVE SUMMARY 79

4 PREMIUM INSIGHT 83

  • 4.1 PESTEL ANALYSIS 85
  • 4.2 PORTER'S FIVE FORCES MODEL 86
  • 4.3 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET ANALYSIS 87
  • 4.4 PATENT ANALYSIS 88

5 PIPELINE ANALYSIS 90

6 EPIDEMIOLOGY 91

7 INDUSTRY INSIGHTS 92

  • 7.1 DEMOGRAPHIC TRENDS 92
  • 7.2 KEY PRICING STRATEGIES 94
  • 7.3 KEY PATIENT ENROLLMENT STRATEGIES 95

8 REGULATORY SCENARIO FOR MEDICAL FOOD 97

9 MARKET OVERVIEW 100

  • 9.1 DRIVERS 102
    • 9.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM (IEM) 102
    • 9.1.2 RISING PREFERENCE FOR DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY (ERT) 103
    • 9.1.3 INCREASE IN THE NUMBER OF NEW-BORN SCREENING PROCEDURES 104
    • 9.1.4 INCREASING SPENDING ON MEDICAL FOOD PRODUCTS 105
  • 9.2 RESTRAINTS 106
    • 9.2.1 HIGH COST OF MEDICAL FOODS 106
    • 9.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 107
  • 9.3 OPPORTUNITIES 108
    • 9.3.1 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT INBORN ERRORS OF METABOLISM 108
    • 9.3.2 INCREASING COLLABORATIONS AND PARTNERSHIPS IN THE MARKET 110
    • 9.3.3 EXPANSION OF MEDICAL FOODS IN EMERGING MARKETS 110
  • 9.4 CHALLENGES 111
    • 9.4.1 POOR ACCESSIBILITY OF MEDICAL FOODS 111
    • 9.4.2 ALTERNATIVE TREATMENT APPROACHES FOR INBORN ERRORS OF METABOLISM 112

10 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 113

  • 10.1 OVERVIEW 114
  • 10.2 AMINO ACID 117
    • 10.2.1 AMINO ACID MIXTURES 118
      • 10.2.1.1 PHENYLADE 119
        • 10.2.1.1.1 DRINK MIX 119
        • 10.2.1.1.2 GMP MIX-IN 119
        • 10.2.1.1.3 GMP READY 119
        • 10.2.1.1.4 OTHERS 119
      • 10.2.1.2 PERIFLEX 119
      • 10.2.1.3 LOPHLEX 120
      • 10.2.1.4 PHLEXY 120
      • 10.2.1.5 COOLER 120
      • 10.2.1.6 ANAMIX 120
      • 10.2.1.7 LYSINE-FREE, LOW TRYPTOPHAN 120
      • 10.2.1.8 GLUTARADE ESSENTIAL GA-1 120
      • 10.2.1.9 GLUTARADE GA-1 AMINO ACID BLEND 120
      • 10.2.1.10 GLYTACTIN WITH GMP 120
      • 10.2.1.11 ESSENTIAL AMINO ACID MIX 120
      • 10.2.1.12 LIQUIGEN 120
      • 10.2.1.13 MSUD GEL 121
      • 10.2.1.14 OTHERS 121
    • 10.2.2 SINGLE AMINO ACID 121
      • 10.2.2.1 L-ARGININE 121
      • 10.2.2.2 L-ISOLEUCINE 121
      • 10.2.2.3 L-TYROSINE 122
      • 10.2.2.4 L-LEUCINE 122
      • 10.2.2.5 GLYCINE 122
      • 10.2.2.6 L-ASPARTIC ACID 122
      • 10.2.2.7 L-CITRULLINE 122
      • 10.2.2.8 OTHERS 122
  • 10.3 LOW PROTEIN FOOD 122
    • 10.3.1 LOW-PROTEIN BAKING MIXES AND FLOUR SUBSTITUTES, SUCH AS RICE FLOUR OR POTATO FLOUR 124
    • 10.3.2 LOW-PROTEIN ENERGY BARS AND SNACKS 124
    • 10.3.3 LOW-PROTEIN CEREALS AND BREAKFAST FOOD 124
    • 10.3.4 LOW-PROTEIN MILK SUBSTITUTES, SUCH AS RICE MILK OR ALMOND MILK 124
    • 10.3.5 LOW-PROTEIN BREAD, PASTA, AND OTHER GRAIN-BASED PRODUCTS 124
    • 10.3.6 OTHERS 124
  • 10.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 124
    • 10.4.1 BY FLAVOUR 125
      • 10.4.1.1 VANILLA 125
      • 10.4.1.2 BERRY 125
      • 10.4.1.3 ORANGE 126
      • 10.4.1.4 PLAIN 126
      • 10.4.1.5 OTHERS 126
    • 10.4.2 BY USAGE 126
      • 10.4.2.1 READY TO DRINK 126
      • 10.4.2.2 NEED DILUTION/PREPARATION 126
  • 10.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 127
    • 10.5.1 NO CALCIUM OR VITAMIN D 128
    • 10.5.2 LOW CALCIUM, NO VITAMIN D 128
    • 10.5.3 OTHERS 128
  • 10.6 OTHERS 128

11 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 130

  • 11.1 OVERVIEW 131
  • 11.2 PHENYLKETONURIA (PKU) 134
    • 11.2.1 PHENYLADE 135
    • 11.2.2 PERIFLEX 135
    • 11.2.3 LOPHLEX 135
    • 11.2.4 OTHERS 135
  • 11.3 TYROSINEMIA TYPES I AND II 135
  • 11.4 MAPLE SYRUP URINE DISEASE (MSUD) 136
    • 11.4.1 ANAMIX 137
    • 11.4.2 COOLER 137
    • 11.4.3 MSUD GEL 137
    • 11.4.4 AMINO ACID BLEND 137
    • 11.4.5 MAXMUM 137
    • 11.4.6 OTHERS 137
  • 11.5 HOMOCYSTINURIA 138
  • 11.6 GLUTARIC ACIDEMIA TYPE I 138
  • 11.7 UREA CYCLE DISORDERS 139
    • 11.7.1 ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) 140
    • 11.7.2 CARBAMYL PHOSPHATE SYNTHETASE DEFICIENCY (CPS) 140
    • 11.7.3 CITRULLINAEMIA 140
    • 11.7.4 N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY (NAGS) 140
    • 11.7.5 ARGINASE DEFICIENCY (AG) 141
    • 11.7.6 ARGININOSUCCINIC ACIDURIA (ASA) 141
    • 11.7.7 OTHERS 141
  • 11.8 METHYLMALONIC ACIDEMIA 141
  • 11.9 ISOVALERIC ACIDEMIA 142
  • 11.10 ORGANIC ACIDURIAS 143
  • 11.11 RENAL DISEASE 143
  • 11.12 PROPIONIC ACIDEMIA 144
  • 11.13 DISORDERS OF LEUCINE METABOLISM 145
  • 11.14 OTHERS 146

12 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 147

  • 12.1 OVERVIEW 148
  • 12.2 INFANTS 151
  • 12.3 WEANING 151
  • 12.4 ADOLESCENT 152
  • 12.5 ADULTS 153

13 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS 154

  • 13.1 OVERVIEW 155
  • 13.2 POWDER 158
  • 13.3 LIQUID 158
  • 13.4 TABLETS 159
  • 13.5 GELS 160
  • 13.6 OTHERS 161

14 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 162

  • 14.1 OVERVIEW 163
  • 14.2 CAN 166
  • 14.3 PACKETS 166
  • 14.4 BOTTLE 167
  • 14.5 JAR 168
  • 14.6 OTHERS 168

15 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 170

  • 15.1 OVERVIEW 171
  • 15.2 HOSPITAL PHARMACY 174
  • 15.3 RETAIL PHARMACY 174
  • 15.4 DRUG STORES 175
  • 15.5 ONLINE PHARMACY 176
  • 15.6 OTHERS 176

16 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 178

  • 16.1 OVERVIEW 179
  • 16.2 NORTH AMERICA 184
    • 16.2.1 U.S. 195
    • 16.2.2 CANADA 202
    • 16.2.3 MEXICO 209
  • 16.3 EUROPE 216
    • 16.3.1 GERMANY 230
    • 16.3.2 FRANCE 239
    • 16.3.3 U.K. 248
    • 16.3.4 ITALY 257
    • 16.3.5 SPAIN 266
    • 16.3.6 SWITZERLAND 276
    • 16.3.7 NETHERLANDS 285
    • 16.3.8 BELGIUM 294
    • 16.3.9 DENMARK 303
    • 16.3.10 RUSSIA 312
    • 16.3.11 SWEDEN 320
    • 16.3.12 TURKEY 328
    • 16.3.13 POLAND 336
    • 16.3.14 FINLAND 344
    • 16.3.15 NORWAY 351
    • 16.3.16 REST OF EUROPE 359
  • 16.4 ASIA-PACIFIC 360
    • 16.4.1 CHINA 375
    • 16.4.2 JAPAN 385
    • 16.4.3 INDIA 394
    • 16.4.4 AUSTRALIA 404
    • 16.4.5 SOUTH KOREA 414
    • 16.4.6 THAILAND 423
    • 16.4.7 SINGAPORE 433
    • 16.4.8 INDONESIA 442
    • 16.4.9 MALAYSIA 451
    • 16.4.10 NEW ZEALAND 460
    • 16.4.11 VIETNAM 468
    • 16.4.12 PHILIPPINES 476
    • 16.4.13 TAIWAN 486
    • 16.4.14 REST OF ASIA-PACIFIC 495
  • 16.5 SOUTH AMERICA 496
    • 16.5.1 BRAZIL 508
    • 16.5.2 ARGENTINA 515
    • 16.5.3 REST OF SOUTH AMERICA 523
  • 16.6 MIDDLE EAST AND AFRICA 524
    • 16.6.1 SOUTH AFRICA 535
    • 16.6.2 SAUDI ARABIA 542
    • 16.6.3 BAHRAIN 549
    • 16.6.4 UNITED ARAB EMIRATES 557
    • 16.6.5 KUWAIT 564
    • 16.6.6 QATAR 572
    • 16.6.7 EGYPT 579
    • 16.6.8 OMAN 586
    • 16.6.9 REST OF MIDDLE EAST AND AFRICA 593

17 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 594

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 594
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 595
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 596
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 597

18 SWOT ANALYSIS 598

19 COMPANY PROFILE 599

  • 19.1 ABBOTT 599
    • 19.1.1 COMPANY SNAPSHOT 599
    • 19.1.2 REVENUE ANALYSIS 599
    • 19.1.3 COMPANY SHARE ANALYSIS 600
    • 19.1.4 PRODUCT PORTFOLIO 600
    • 19.1.5 RECENT DEVELOPMENT 601
  • 19.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE) 602
    • 19.2.1 COMPANY SNAPSHOT 602
    • 19.2.2 COMPANY SHARE ANALYSIS 602
    • 19.2.3 PRODUCT PORTFOLIO 603
    • 19.2.4 RECENT DEVELOPMENT 603
  • 19.3 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 604
    • 19.3.1 COMPANY SNAPSHOT 604
    • 19.3.2 COMPANY SHARE ANALYSIS 604
    • 19.3.3 PRODUCT PORTFOLIO 605
    • 19.3.4 RECENT DEVELOPMENTS 605
  • 19.4 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 606
    • 19.4.1 COMPANY SNAPSHOT 606
    • 19.4.2 COMPANY SHARE ANALYSIS 606
    • 19.4.3 PRODUCT PORTFOLIO 607
    • 19.4.4 RECENT DEVELOPMENT 607
  • 19.5 NUTRICIA (A SUBSIDIARY OF DANONE) 608
    • 19.5.1 COMPANY SNAPSHOT 608
    • 19.5.2 COMPANY SHARE ANALYSIS 608
    • 19.5.3 PRODUCT PORTFOLIO 609
    • 19.5.4 RECENT DEVELOPMENT 610
  • 19.6 APR 611
    • 19.6.1 COMPANY SNAPSHOT 611
    • 19.6.2 PRODUCT PORTFOLIO 611
    • 19.6.3 RECENT DEVELOPMENT 611
  • 19.7 B.BRAUN SE 612
    • 19.7.1 COMPANY SNAPSHOT 612
    • 19.7.2 PRODUCT PORTFOLIO 612
    • 19.7.3 RECENT DEVELOPMENT 612
  • 19.8 BAXTER 613
    • 19.8.1 COMPANY SNAPSHOT 613
    • 19.8.2 REVENUE ANALYSIS 613
    • 19.8.3 PRODUCT PORTFOLIO 614
    • 19.8.4 RECENT DEVELOPMENT 614
  • 19.9 DR. SCHAR AG / SPA 615
    • 19.9.1 COMPANY SNAPSHOT 615
    • 19.9.2 PRODUCT PORTFOLIO 615
    • 19.9.3 RECENT DEVELOPMENT 616
  • 19.10 EBM MEDICAL 617
    • 19.10.1 COMPANY SNAPSHOT 617
    • 19.10.2 PRODUCT PORTFOLIO 617
    • 19.10.3 RECENT DEVELOPMENT 617
  • 19.11 ENER-G FOODS, INC. 618
    • 19.11.1 COMPANY SNAPSHOT 618
    • 19.11.2 PRODUCT PORTFOLIO 618
    • 19.11.3 RECENT DEVELOPMENT 618
  • 19.12 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 619
    • 19.12.1 COMPANY SNAPSHOT 619
    • 19.12.2 PRODUCT PORTFOLIO 619
    • 19.12.3 RECENT DEVELOPMENT 619
  • 19.13 GALEN LIMITED 620
    • 19.13.1 COMPANY SNAPSHOT 620
    • 19.13.2 PRODUCT PORTFOLIO 620
    • 19.13.3 RECENT DEVELOPMENTS 620
  • 19.14 HEXAGONNUTRITION LTD. 621
    • 19.14.1 COMPANY SNAPSHOT 621
    • 19.14.2 PRODUCT PORTFOLIO 621
    • 19.14.3 RECENT DEVELOPMENT 621
  • 19.15 KATE FARMS 622
    • 19.15.1 COMPANY SNAPSHOT 622
    • 19.15.2 PRODUCT PORTFOLIO 622
    • 19.15.3 RECENT DEVELOPMENTS 623
  • 19.16 MEIJI HOLDINGS CO., LTD. 624
    • 19.16.1 COMPANY SNAPSHOT 624
    • 19.16.2 REVENUE ANALYSIS 624
    • 19.16.3 PRODUCT PORTFOLIO 625
    • 19.16.4 RECENT DEVELOPMENT 625
  • 19.17 ORPHARMA PTY LTD. 626
    • 19.17.1 COMPANY SNAPSHOT 626
    • 19.17.2 PRODUCT PORTFOLIO 626
    • 19.17.3 RECENT DEVELOPMENT 626
  • 19.18 PIAM FARMACEUTICI S.P.A 627
    • 19.18.1 COMPANY SNAPSHOT 627
    • 19.18.2 PRODUCT PORTFOLIO 628
    • 19.18.3 RECENT DEVELOPMENT 628
  • 19.19 PKU PERSPECTIVES 629
    • 19.19.1 COMPANY SNAPSHOT 629
    • 19.19.2 PRODUCT PORTFOLIO 629
    • 19.19.3 RECENT DEVELOPMENTS 629
  • 19.20 PKU-MDMIL 630
    • 19.20.1 COMPANY SNAPSHOT 630
    • 19.20.2 PRODUCT PORTFOLIO 630
    • 19.20.3 RECENT DEVELOPMENT 630
  • 19.21 PRIMUS PHARMACEUTICALS, INC. 631
    • 19.21.1 COMPANY SNAPSHOT 631
    • 19.21.2 PRODUCT PORTFOLIO 631
    • 19.21.3 RECENT DEVELOPMENT 631
  • 19.22 PRISTINE ORGANICS PRIVATE LIMITED 632
    • 19.22.1 COMPANY SNAPSHOT 632
    • 19.22.2 PRODUCT PORTFOLIO 633
    • 19.22.3 RECENT DEVELOPMENT 633
  • 19.23 PROMIN METABOLICS 634
    • 19.23.1 COMPANY SNAPSHOT 634
    • 19.23.2 PRODUCT PORTFOLIO 635
    • 19.23.3 RECENT DEVELOPMENT 635
  • 19.24 SOLACE NUTRITION 636
    • 19.24.1 COMPANY SNAPSHOT 636
    • 19.24.2 PRODUCT PORTFOLIO 636
    • 19.24.3 RECENT DEVELOPMENT 637

20 QUESTIONNAIRE 638

21 RELATED REPORTS 642

LIST OF TABLES

  • TABLE 1 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, PATENT ANALYSIS 88
  • TABLE 2 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, PIPELINE ANALYSIS 90
  • TABLE 3 COSTS OF MEDICAL FOODS USED IN INBORN ERRORS OF METABOLISM (IEMS) 94
  • TABLE 4 THE MANUFACTURING OF MEDICAL FOOD MUST COMPLY WITH THE BELOW GIVEN FDA REQUIREMENT: 97
  • TABLE 5 COSTS OF MEDICAL FOODS 106
  • TABLE 6 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-20307 (USD MILLION) 116
  • TABLE 7 GLOBAL AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 8 GLOBAL AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 117
  • TABLE 9 GLOBAL AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 118
  • TABLE 10 GLOBAL PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 119
  • TABLE 11 GLOBAL SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 121
  • TABLE 12 GLOBAL LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2018-2030 (USD MILLION) 123
  • TABLE 13 GLOBAL LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 123
  • TABLE 14 GLOBAL GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 15 GLOBAL GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVOURS, 2021-2030 (USD MILLION) 125
  • TABLE 16 GLOBAL GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGE, 2021-2030 (USD MILLION) 126
  • TABLE 17 GLOBAL LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 18 GLOBAL LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 127
  • TABLE 19 GLOBAL OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 20 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 133
  • TABLE 21 GLOBAL PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 22 GLOBAL PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 134
  • TABLE 23 GLOBAL TYROSINEMIA TYPES I AND II IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 24 GLOBAL MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 25 GLOBAL MAPLE SYRUP URINE DISEASE(MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2018-2030 (USD MILLION) 137
  • TABLE 26 GLOBAL HOMOCYSTINURIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 27 GLOBAL GLUTARIC ACIDEMIA TYPE I IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 28 GLOBAL UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 29 GLOBAL UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 140
  • TABLE 30 GLOBAL METHYLMALONIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 141
  • TABLE 31 GLOBAL ISOVALERIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 142
  • TABLE 32 GLOBAL ORGANIC ACIDURIAS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 33 GLOBAL RENAL DISEASE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2018-2030 (USD MILLION) 144
  • TABLE 34 GLOBAL PROPIONIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 144
  • TABLE 35 GLOBAL DISORDERS OF LEUCINE METABOLISM IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 36 GLOBAL OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 37 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 150
  • TABLE 38 GLOBAL INFANTS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 151
  • TABLE 39 GLOBAL WEANING IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 152
  • TABLE 40 GLOBAL ADOLESCENT IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 152
  • TABLE 41 GLOBAL ADULTS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 153
  • TABLE 42 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 157
  • TABLE 43 GLOBAL POWDER IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 158
  • TABLE 44 GLOBAL LIQUID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 159
  • TABLE 45 GLOBAL TABLETS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 159
  • TABLE 46 GLOBAL GELS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 160
  • TABLE 47 GLOBAL OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 161
  • TABLE 48 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 165
  • TABLE 49 GLOBAL CAN IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 166
  • TABLE 50 GLOBAL PACKETS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 167
  • TABLE 51 GLOBAL BOTTLE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 167
  • TABLE 52 GLOBAL JAR IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 168
  • TABLE 53 GLOBAL OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 169
  • TABLE 54 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 173
  • TABLE 55 GLOBAL HOSPITAL PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 174
  • TABLE 56 GLOBAL RETAIL PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 175
  • TABLE 57 GLOBAL DRUG STORES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 175
  • TABLE 58 GLOBAL ONLINE PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 176
  • TABLE 59 GLOBAL OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 177
  • TABLE 60 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 183
  • TABLE 61 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 188
  • TABLE 62 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 188
  • TABLE 63 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 188
  • TABLE 64 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 189
  • TABLE 65 NORTH AMERICA PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 189
  • TABLE 66 NORTH AMERICA SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 190
  • TABLE 67 NORTH AMERICA LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 190
  • TABLE 68 NORTH AMERICA GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 191
  • TABLE 69 NORTH AMERICA GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 191
  • TABLE 70 NORTH AMERICA LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 191
  • TABLE 71 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 192
  • TABLE 72 NORTH AMERICA PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 192
  • TABLE 73 NORTH AMERICA MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 193
  • TABLE 74 NORTH AMERICA UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 193
  • TABLE 75 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 193
  • TABLE 76 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 194
  • TABLE 77 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 194
  • TABLE 78 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 194
  • TABLE 79 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 195
  • TABLE 80 U.S. AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 195
  • TABLE 81 U.S. AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 196
  • TABLE 82 U.S. PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 196
  • TABLE 83 U.S. SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 197
  • TABLE 84 U.S. LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 197
  • TABLE 85 U.S. GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 198
  • TABLE 86 U.S. GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 198
  • TABLE 87 U.S. LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 198
  • TABLE 88 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 199
  • TABLE 89 U.S. PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 199
  • TABLE 90 U.S. MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 200
  • TABLE 91 U.S. UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 200
  • TABLE 92 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 200
  • TABLE 93 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 201
  • TABLE 94 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 201
  • TABLE 95 U.S. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 201
  • TABLE 96 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 202
  • TABLE 97 CANADA AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 202
  • TABLE 98 CANADA AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 203
  • TABLE 99 CANADA PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 203
  • TABLE 100 CANADA SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 204
  • TABLE 101 CANADA LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 204
  • TABLE 102 CANADA GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 205
  • TABLE 103 CANADA GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 205
  • TABLE 104 CANADA LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 205
  • TABLE 105 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 206
  • TABLE 106 CANADA PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 206
  • TABLE 107 CANADA MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 207
  • TABLE 108 CANADA UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 207
  • TABLE 109 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 207
  • TABLE 110 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 208
  • TABLE 111 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 208
  • TABLE 112 CANADA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 208
  • TABLE 113 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 209
  • TABLE 114 MEXICO AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 209
  • TABLE 115 MEXICO AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 210
  • TABLE 116 MEXICO PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 210
  • TABLE 117 MEXICO SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 211
  • TABLE 118 MEXICO LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 211
  • TABLE 119 MEXICO GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 212
  • TABLE 120 MEXICO GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 212
  • TABLE 121 MEXICO LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 212
  • TABLE 122 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 213
  • TABLE 123 MEXICO PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 213
  • TABLE 124 MEXICO MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 214
  • TABLE 125 MEXICO UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 214
  • TABLE 126 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 214
  • TABLE 127 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 215
  • TABLE 128 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 215
  • TABLE 129 MEXICO MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 215
  • TABLE 130 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 220

LIST OF FIGURES

  • FIGURE 1 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SEGMENTATION 68
  • FIGURE 2 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DATA TRIANGULATION 71
  • FIGURE 3 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DROC ANALYSIS 72
  • FIGURE 4 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 73
  • FIGURE 5 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY RESEARCH ANALYSIS 73
  • FIGURE 6 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: INTERVIEW DEMOGRAPHICS 74
  • FIGURE 7 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DBMR MARKET POSITION GRID 76
  • FIGURE 8 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SEGMENTATION 81
  • FIGURE 9 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE THE FASTEST-GROWING REGION WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 82
  • FIGURE 10 A RISE IN THE INCIDENCE OF INBORN ERRORS OF METABOLISM AND AN INCREASE IN THE NUMBER OF THE NEWBORN SCREENING PROCEDURES ARE EXPECTED TO DRIVE THE GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 83
  • FIGURE 11 THE AMINO ACID SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET IN 2023 AND 2030 83
  • FIGURE 12 ASIA-PACIFIC IS THE MAXIMUM GROWING REGION FOR THE GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 84
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET 101
  • FIGURE 14 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, 2022 114
  • FIGURE 15 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, 2023-2030 (USD MILLION) 115
  • FIGURE 16 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, CAGR (2023-2030) 115
  • FIGURE 17 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, LIFELINE CURVE 116
  • FIGURE 18 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, 2022 131
  • FIGURE 19 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, 2023-2030 (USD MILLION) 132
  • FIGURE 20 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, CAGR (2023-2030) 132
  • FIGURE 21 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, LIFELINE CURVE 133
  • FIGURE 22 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, 2022 148
  • FIGURE 23 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 149
  • FIGURE 24 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, CAGR (2023-2030) 149
  • FIGURE 25 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, LIFELINE CURVE 150
  • FIGURE 26 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, 2022 155
  • FIGURE 27 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, 2023-2030 (USD MILLION) 156
  • FIGURE 28 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, CAGR (2023-2030) 156
  • FIGURE 29 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, LIFELINE CURVE 157
  • FIGURE 30 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, 2022 163
  • FIGURE 31 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, 2023-2030 (USD MILLION) 164
  • FIGURE 32 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, CAGR (2023-2030) 164
  • FIGURE 33 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, LIFELINE CURVE 165
  • FIGURE 34 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, 2022 171
  • FIGURE 35 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 172
  • FIGURE 36 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 172
  • FIGURE 37 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 173
  • FIGURE 38 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 180
  • FIGURE 39 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY REGION (2022) 181
  • FIGURE 40 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY REGION (2023 & 2030) 181
  • FIGURE 41 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY REGION (2022 & 2030) 182
  • FIGURE 42 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 182
  • FIGURE 43 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 185
  • FIGURE 44 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 186
  • FIGURE 45 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 186
  • FIGURE 46 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 187
  • FIGURE 47 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 187
  • FIGURE 48 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 217
  • FIGURE 49 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 218
  • FIGURE 50 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 218
  • FIGURE 51 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 219
  • FIGURE 52 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 219
  • FIGURE 53 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 361
  • FIGURE 54 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 362
  • FIGURE 55 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 362
  • FIGURE 56 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 363
  • FIGURE 57 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 363
  • FIGURE 58 SOUTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 497
  • FIGURE 59 SOUTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 498
  • FIGURE 60 SOUTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 498
  • FIGURE 61 SOUTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 499
  • FIGURE 62 SOUTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 499
  • FIGURE 63 MIDDLE EAST AND AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 525
  • FIGURE 64 MIDDLE EAST AND AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 526
  • FIGURE 65 MIDDLE EAST AND AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 526
  • FIGURE 66 MIDDLE EAST AND AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 527
  • FIGURE 67 MIDDLE EAST AND AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 527
  • FIGURE 68 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY SHARE 2022 (%) 594
  • FIGURE 69 NORTH AMERICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY SHARE 2022 (%) 595
  • FIGURE 70 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY SHARE 2022 (%) 596
  • FIGURE 71 ASIA-PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY SHARE 2022 (%) 597